MSTO-211H細(xì)胞

生長狀態(tài)： 貼壁生長

年限： 62 years

是否是腫瘤細(xì)胞： 1

物種來源： 人

ATCC Number： CRL-2081?

相關(guān)**： 其他**

運輸方式： 凍存運輸

細(xì)胞形態(tài)： 成纖維樣

數(shù)量： 大量

Designations: MSTO-211H

Depositors: G Bepler

Biosafety Level: 1

MSTO-211H細(xì)胞Shipped: frozen

Medium & Serum: See Propagation

Growth Properties: adherent

Organism: Homo sapiens

Morphology: fibroblast

Source: Disease: biphasic mesothelioma

Derived from metastatic site: lung

Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Isolation: Isolation date: 1985

Tumorigenic: Yes

Oncogene: c-myc +; v-src +; v-abl +; v-erb B +; c-raf 1 +; H-ras +; K-ras +; N-ras +; N-myc -; L-myc -; c-myb -; c-fos -; v-fes -; v-fms -; v-sis -

DNA Profile (STR): Amelogenin: X,Y

CSF1PO: 11,12

D13S317: 11,14

MSTO-211H細(xì)胞D16S539: 13

D5S818: 12

D7S820: 8,12

THO1: 8,9.3

TPOX: 11

vWA: 16,18

Cytogenetic Analysis: modal number = 72; range = 70 to 78

Age: 62 years

Gender: male

Ethnicity: Caucasian

Comments: The MSTO-211H cell line was established in 1985 from the pleural effusion of a patient with biphasic mesothelioma of the lung.

The patient had not received prior radiation or chemotherapy.

MSTO-211H cells have high affinity binding sites for EGF, and express Neuron specific enolase (NSE) and both the alpha and beta subunits of human chorionic gonadotropin (HCG).

L-DOPA decarboxylase (DDC), bombesin and neurotensin were not detected.

The cells overexpress the c-myc protooncogene, and no gene rearrangement or amplification was observed.

They are positive for the expression of v-src, v-abl, v-erb B, c-raf 1, Ha-ras, Ki-ras, and N-ras.

MSTO-211H細(xì)胞Expression of N-myc, L-myc, c-myb, c-fos, v-fes, v-fms and v-sis oncogene expression was not detected.

The cells can reach a saturation density of 400000 cells per sq cm, but will slough off of the surface as they attain this density.

Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.

Temperature: 37.0°C

Subculturing: Protocol:

Remove and discard culture medium.

Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum which contains trypsin inhibitor.

Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).

Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37?C to facilitate dispersal.

Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.

Add appropriate aliquots of the cell suspension to new culture vessels.

Incubate cultures at 37?C.

Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:6 is recommended

Medium Renewal: Every 2 to 3 days

Preservation: Freeze medium: Complete growth medium 95%; DMSO, 5%

Storage temperature: liquid nitrogen vapor phase

Doubling Time: 20 hrs

Related Products: Recommended medium MSTO-211H細(xì)胞(without the additional supplements or serum described under ATCC Medium):ATCC 30-2001

recommended serum:ATCC 30-2020

References: 22261: Bepler G, Koehler A. Multiple chromosomal aberrations and 11p allelotyping in lung cancer cell lines. Cancer Genet. Cytogenet. 84: 39-45, 1995. PubMed: 7497441

22745: Bepler G, et al. Characterization of the state of differentiation of six newly established human non-small-cell lung cancer cell lines. Differentiation 37: 158-171, 1988. PubMed: 2840315

23067: Haeder M, et al. Epidermal growth factor receptor expression in human lung cancer cell lines. Cancer Res. 48: 1132-1136, 1988. PubMed: 2830015

24389: . . Lung Cancer 4: 155-161, 1988.